D
Derek Raghavan
Researcher at Carolinas Healthcare System
Publications - 283
Citations - 22871
Derek Raghavan is an academic researcher from Carolinas Healthcare System. The author has contributed to research in topics: Bladder cancer & Cancer. The author has an hindex of 50, co-authored 266 publications receiving 20944 citations. Previous affiliations of Derek Raghavan include University of Chicago & Roswell Park Cancer Institute.
Papers
More filters
Journal ArticleDOI
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
Daniel P. Petrylak,Catherine M. Tangen,Maha Hussain,Primo N. Lara,Jeffrey A. Jones,Mary-Ellen Taplin,Patrick A. Burch,Donna L. Berry,Carol M. Moinpour,Manish Kohli,Mitchell C. Benson,Eric J. Small,Derek Raghavan,E. David Crawford +13 more
TL;DR: The improvement in median survival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer.
Journal ArticleDOI
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
John P. Stein,Gary Lieskovsky,Richard J. Cote,Susan Groshen,An-Chen Feng,Stuart D. Boyd,Eila C. Skinner,Bernard H. Bochner,Duriayai Thangathurai,Maged Mikhail,Derek Raghavan,Donald G. Skinner +11 more
TL;DR: These data from a large group of patients support the aggressive surgical management of invasive bladder cancer and suggest excellent long-term survival can be achieved with a low incidence of pelvic recurrence.
Journal ArticleDOI
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
H. Barton Grossman,Ronald B. Natale,Catherine M. Tangen,V. O. Speights,Nicholas J. Vogelzang,Donald L. Trump,Ralph W deVere White,Michael F. Sarosdy,David P. Wood,Derek Raghavan,E. David Crawford +10 more
TL;DR: Using neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy increases the likelihood of eliminating residual cancer in the Cystectomy specimen and is associated with improved survival among patients with locally advanced bladder cancer.
Journal ArticleDOI
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono,Howard I. Scher,R. Bruce Montgomery,Chris Parker,M. Craig Miller,H. Tissing,Gerald V. Doyle,Leon W.W.M. Terstappen,Kenneth J. Pienta,Derek Raghavan +9 more
TL;DR: CTC are the most accurate and independent predictor of OS in CRPC, and this data led to Food and Drug Administration clearance of this assay for the evaluation of CRPC.
Journal ArticleDOI
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
Lowell E. Schnipper,Nancy E. Davidson,Dana S. Wollins,Courtney Tyne,Douglas W. Blayney,Diane Blum,Adam P. Dicker,Patricia A. Ganz,J. Russell Hoverman,Robert M. Langdon,Gary H. Lyman,Neal J. Meropol,Therese M. Mulvey,Lee N. Newcomer,Jeffrey Peppercorn,Blase N. Polite,Derek Raghavan,Gregory Rossi,Leonard B. Saltz,Deborah Schrag,Thomas J. Smith,Peter Paul Yu,Clifford A. Hudis,Richard L. Schilsky +23 more
TL;DR: The high costs associated with cancer care have created a difficult situation for patients and the oncologists who care for them and will require greater understanding of all the risks and benefits of various treatment options as well as the consequences of specific choices.